NCT00396240View on ClinicalTrials.gov

ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

PHASE4WithdrawnINTERVENTIONAL
Enrollment

1,294

Participants

Timeline

Start Date

February 28, 2002

Conditions
Primary Hypercholesterolaemia
Interventions
DRUG

Rosuvastatin

PROCEDURE

Initiatives to improve compliance

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY